BioSight
Companies
Cellectis S.A. logo

CLLS

NASDAQPARIS, LLE-DE-FRANCE
Cellectis S.A.

Cellectis S.A. is a clinical-stage biopharmaceutical company developing allogeneic CAR T-cell immunotherapy product candidates for oncology applications, with development governed by complex and evolving regulatory frameworks for cell therapy and gene therapy products. The company has a significant collaboration with AstraZeneca through a Joint Research and Collaboration Agreement dated November 1, 2023, under which 25 genetic targets have been exclusively reserved for AstraZeneca with options for up to 10 candidate products.

Price history not yet available for CLLS.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar